Explore All 528 Venture Information Technology Deals - Search the Database Free
Investment Summary |
|
|---|---|
| Date | December 1, 2009 |
| Target | BoosterMedia |
| Sector | Information Technology |
| Investor(s) | Truffle Capital |
| Deal Type | Venture |
FILTER BY
| Category | Private Equity Firm |
|---|---|
| Founded | 2001 |
| PE ASSETS | 700M EUR |
| Size | Middle-Market |
| Type | Sector Focused |
Truffle Capital is a French private equity firm focused on majority investments in life science and information technology companies. Within IT, Truffle seeks businesses dealing in mobile content and connectivity, internet, technical software, IT security, and VOIP. Within the life science sector, the Firm looks at opportunities in therapeutic drugs and vaccines, medical devices, as well as other breakthrough technologies. Truffle Capital was formed in 2001 and is based in Paris.
| Deal Context for Investor | # |
|---|---|
| Overall | 30 of 45 |
| Sector: Information Technology | 3 of 4 |
| Type: Venture | 5 of 8 |
| Country: Netherlands | 3 of 3 |
| Year: 2009 | 4 of 4 |
| DATE | TARGET | DEAL TYPE | VALUE |
|---|---|---|---|
| 2009-12-01 |
BMD
Marne La Vallee, France BMD is a vitro diagnostic company focused on auto-immunity and infectious diseases, based in Marne La Vallee , France. |
Buy | €3M |
| DATE | TARGET | DEAL TYPE | VALUE |
|---|---|---|---|
| 2010-02-17 |
Immune Targeting Systems
London, United Kingdom Immune Targeting Systems Ltd. develops synthetic vaccines for mutating viruses. Immune Targeting Systems enabling the T-cell vaccine platform enables it to target highly conserved parts of the virus (“antigens”) and direct a T-cell immune response to those cells in the body infected with one of these difficult viruses. Immune Targeting Systems was founded in 2003 and is based in London, United Kingdom. |
Buy | - |
